| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 2,104 | 2,487 | ||
| General and administrative | 1,863 | 2,714 | ||
| Severance and related charges | 0 | - | ||
| Total operating expenses | 3,967 | 5,201 | ||
| Interest income | 113 | 107 | ||
| Loss from operations | -3,854 | -5,094 | ||
| Net loss | -3,854 | -5,094 | ||
| Net loss per share - basic | -0.85 | -1.24 | ||
| Net loss per share - diluted | -0.85 | -1.24 | ||
| Weighted-average number of shares used in computing net loss per common share, basic | 4,537,683 | 4,119,153 | ||
| Weighted-average number of shares used in computing net loss per common share, diluted | 4,537,683 | 4,119,153 | ||
IN8BIO, INC. (INAB)
IN8BIO, INC. (INAB)